ERCC1 as a Predictive Marker for FOLFOX Chemotherapy in an Adjuvant Setting

Kim, Chee Young; Seo, Sang Hyuk; An, Min Sung; Kim, Kwang Hee; Bae, Ki Beom; Hwang, Jin Won; Kim, Ji Hyun; Kim, Bo Mi; Kang, Mi Seon; Oh, Min Jun; Hong, Kwan Hee

doi:10.3393/ac.2015.31.3.92

Cited by 8 publications

(4 citation statements)

References 25 publications

(31 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, ERCC1 positive expression was significantly associated with older age group patients (P = 0.031). [17] Also it has been shown in patients with nasopharyngeal carcinoma that the expression level of ERCC1 increased significantly with higher T stage and clinical stages (P < 0.05). Thus, at least in that malignancy, ERCC1 seemed to be a valid biological indicator to predict prognosis.…”

Section: Discussionmentioning

confidence: 95%

ERCC1 expression in patients with colorectal cancer: a pilot study

Gajjar¹,

Yadav²,

Kobawala³

et al. 2016

JCMT

View full text Add to dashboard Cite

Aim: Excision repair cross complementation group 1 (ERCC1) has a key role in enhanced DNA damage repair caused by oxaliplatin-based therapy and may lead to resistance of these platinum drugs in colorectal cancer (CRC) patients. Hence, the present preliminary study aimed to explore the role of ERCC1 C/T polymorphism at codon 118 as well as its immunoreactivity in patients with primary CRC. Methods: ERCC1 polymorphism was studied using PCR-RFLP and ERCC1 protein expression was examined by immunohistochemistry in 50 CRC patients. Results: ERCC1 codon 118 C/T polymorphism analysis reported the predominance of C/T (52%) genotype as compared to C/C (38%) and T/T (10%) genotypes. Furthermore, 72% of patients showed positive ERCC1 protein expression. Significant correlation was not observed between clinicopathological parameters and ERCC1 polymorphism, while ERCC1 protein expression significantly correlated only with tumor site (colon vs. rectum) (P = 0.046). Further, the present study failed to demonstrate the role of ERCC1 C118T polymorphism or protein expression as useful prognostic markers in CRC patients. Conclusion: ERCC1-positive protein expression may be a useful marker for rectal cancer patients. However, further evaluation in a larger set of CRC patients is required to better understand the role of ERCC1. Key words:Excision repair cross complementation group 1, oxaliplatin, colorectal cancer, polymorphism, protein expression, PCR-RFLP, immunohistochemistry ABSTRACTArticle history:

show abstract

Section: Discussionmentioning

confidence: 95%

ERCC1 expression in patients with colorectal cancer: a pilot study

Gajjar¹,

Yadav²,

Kobawala³

et al. 2016

JCMT

View full text Add to dashboard Cite

show abstract

“…ERCC1 and MGMT are known to be related to oxaliplatin-and alkylating-agent-based treatment [29,30]. Considering this, these repair enzymes might help predict FOLFOX resistance.…”

Section: Discussionmentioning

confidence: 99%

ERCC1 and MGMT Methylation as a Predictive Marker of Relapse and FOLFOX Response in Colorectal Cancer Patients from South Tunisia

Jamai

Gargouri

Selmi

et al. 2023

Genes

View full text Add to dashboard Cite

Genetic and epigenetic modifications present a major cause of relapse and treatment failure in colorectal cancer. This study aims to appreciate the prognostic and predictive value of ERRC1 and MGMT methylation. We also studied the prognostic impact of the ERCC1 rs11615 polymorphism as well as its expression. Methylation profiles of ERCC1 and MGMT were tested by methylation-specific PCR. A polymorphism of ERCC1 was studied using PCR-RFLP and its expression was examined by immunohistochemistry. ERCC1 was methylated in 44.6% of colorectal adenocarcinoma while MGMT was methylated in 69% of cases. MGMT methylation was strongly associated with lymph node metastasis, lymph invasion, venous invasion, perineural invasion, distant metastasis and relapse. Patients with methylation of both genes were more likely to have a poor prognosis and display chemoresistance. IHC analysis revealed that ERCC1 staining was noted in 52.8% of colorectal adenocarcinoma and inversely related to distant metastasis and cancer recurrence. Kaplan Meier analysis revealed that the worst overall survival was significantly associated with ERCC1 and MGMT methylation while decreased ERCC1 expression and T/T genotype exhibited the best overall survival. The methylation of MGMT, alone or combined with ERCC1, is predictive for poor prognosis, short overall survival and chemotherapy response in colorectal cancer.

show abstract

“…Similar conclusions were achieved by Kim et al in stage II and stage III CRC patients who underwent a curative resection followed by FOLFOX-4 adjuvant chemotherapy. ERCC1 expression was not significantly correlated with the 5-year DFS ( p = 0.396) and therefore cannot be used as a prognostic factor [ 43 ].…”

Section: Oxaliplatinmentioning

confidence: 99%

Predictive Biomarkers in Colorectal Cancer: From the Single Therapeutic Target to a Plethora of Options

Rodrigues

Longatto‐Filho

Martins

2016

BioMed Research International

View full text Add to dashboard Cite

Colorectal cancer (CRC) is one of the most frequent cancers and is a leading cause of cancer death worldwide. Treatments used for CRC may include some combination of surgery, radiation therapy, chemotherapy, and targeted therapy. The current standard drugs used in chemotherapy are 5-fluorouracil and leucovorin in combination with irinotecan and/or oxaliplatin. Most recently, biologic agents have been proven to have therapeutic benefits in metastatic CRC alone or in association with standard chemotherapy. However, patients present different treatment responses, in terms of efficacy and toxicity; therefore, it is important to identify biological markers that can predict the response to therapy and help select patients that would benefit from specific regimens. In this paper, authors review CRC genetic markers that could be useful in predicting the sensitivity/resistance to chemotherapy.

show abstract

ERCC1 as a Predictive Marker for FOLFOX Chemotherapy in an Adjuvant Setting

Cited by 8 publications

References 25 publications

ERCC1 expression in patients with colorectal cancer: a pilot study

ERCC1 expression in patients with colorectal cancer: a pilot study

ERCC1 and MGMT Methylation as a Predictive Marker of Relapse and FOLFOX Response in Colorectal Cancer Patients from South Tunisia

Predictive Biomarkers in Colorectal Cancer: From the Single Therapeutic Target to a Plethora of Options

Contact Info

Product

Resources

About